Advertisement

Topics

Athera Biotechnologies Initiates Phase IIa Trial On Arterial Inflammation With Its Antibody PC-mAb

20:00 EDT 10 Oct 2017 | BioSpace

Athera initiates Phase 2a trial on arterial inflammation with its antibody PC-mAb Stockholm October 11, 2017 Athera Biotechnologies AB today announced that screening has started for a Phase 2a prospective, double-blind, randomised, placebo-controlled multicentre study to investigate the effects of treatment on arterial inflammation with PC-mAb. The study populati...

Original Article: Athera Biotechnologies Initiates Phase IIa Trial On Arterial Inflammation With Its Antibody PC-mAb

NEXT ARTICLE

More From BioPortfolio on "Athera Biotechnologies Initiates Phase IIa Trial On Arterial Inflammation With Its Antibody PC-mAb"

Quick Search
Advertisement
 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...